dapagliflozin + telmisartan

Dapagliflozin + telmisartan is a fixed-dose combination therapy comprising dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and telmisartan, an angiotensin II receptor blocker (ARB). Dapagliflozin reduces blood glucose by inhibiting renal glucose reabsorption, leading to glycosuria, while telmisartan lowers blood pressure by selectively blocking angiotensin II type 1 (AT1) receptors to inhibit vasoconstriction and aldosterone secretion. This combination is considered for the management of patients who require glycemic control (type 2 diabetes mellitus) and antihypertensive therapy, with potential added benefits on cardiovascular and renal risk reduction. No fixed-brand name formulation is widely marketed as of September 2025, but both components are established as individual agents[2][5].

Brand names

Dapatelmi

Other names

telmisartan/dapagliflozin - THPharm